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843FO-6 The Neurohumoral and Hemodynamic Effects of Acute 
Vasopeptidase InhlblUon In Experimental Hypertension 
Calin v. Maniu, Donna M. Meyer, Margaret M. Redfield, Mayo C/inic, Rochester, 
Minnesota. 
Background: Vasopeptidase inhibitors (VPt) are a novel class of antihypertensive 
agents which inhibit angiotensin converting enzyme as well as peptideses which degrade 
atrial (ANP) and brain (BNP) natduretic peptides and adrenomedullin (ADM). Whether 
VPI therapy augments these hormones in hypertension (HTN) is unclear. Further, the 
hemodynamic mechanisms whereby VPI lower blood pressure are ill defined. 
Methods: Dogs (n=8) were made hypertensive by renal wrapping (mean arterial pres- 
sure = 171+-10 mm Hg at 4 weeks). After 5-8 weeks of HTN, dogs were instrumented for 
chronic conscious assessment of LV pressure (LVP) and volume (LVV). Two weeks later, 
hemodynamics and hormone levels were assessed before and 30 and 60 minutes after 
acute VPI infusion (omapatrilat, 30 p.M/kg iv). 
Results: Table (* = p<O.05 vs. baseline, # = p<0.05 vs. before renal wrap) Experimental 
HTN resulted in increases in plasma BNP but not ANP and a trend towards increased 
ADM (p=0.15). Acute VPI resulted in marked decreases in systolic and end-diastolic LVP 
and LVV. Acute VPI increased plasma ADM, decreased BNP but had no effect on ANP. 
Conclusions: In experimental HTN profound decreases in preload occur with VPI and 
contribute to the antihypertensive effect. While ANP did not decrease despite a reduction 
in filling pressures, the decrease in LV systolic pressure was associated with a reduction 
in BNP. These data suggest that VPI induced augmentation of ADM rather than natri- 
uretic peptides is contdbutin~ to its antihypertensive effect. 
Before renal wrap Baseline 30 minutes 60 minutes 
Systolic LVP mm Hg 169+_22 111±15" 113+15" 
End-diastolic LVP mm Hg 14+4 4±3" 5+3* 
End-diastolic LVV mL 50±9 39+-7* 40±7* 
ADM pg/mL 21±1 38±10 74±20* 74±16" 
BNP pg/mL 34±7 420~134 # 285±68 234+81" 
ANP pg/mL 108±33 72+~?,3 93_+30 87±27 
1151-70 Heavy and Light Cigarette Smokers Have a Similar 
Dysfunction In NO Biosynthesis: An In Vivo and In Vitro 
Correlation 
Raiat S. Barua. John A. Ambrose, Lesley-Jane Eales-Reynotds, Mary C. DeVoe, John G. 
Zarvas, Dhanonjoy C. Saha, Saint Vincent Catholic Medical Centers of New York, New 
York, The School of Biomedical and Life Sciences, University of Surrey, Guildford, United 
Kingdom. 
Background:. Limited studies suggest that cigaretle smoking may be associated with a 
dose-dependent decrease of endothelium-dependent vasodilatatJon (EDV). This dose 
specific effect on the nitric oxide (NO) biosynthetic pathway is not known. In the current 
study effects of light (_<1 pk/week) and heavy (->1 pk/day) smoking on brachial artery 
reactivity in vivo were directly correlated with the NO biosynthetic pathway in vitro using 
serum from the same individuals. 
Methods: Brachial artery reactivity to flow (endothelium-dependent) and nitroglycerin 
(endothelium-independent) were measured in 8 nonsmokers (NS), 8 heavy smokers 
(HS) and 7 light smokers (LS). Serum from each subject was incubated with confluent 
(-85%) human umbilical endothelial cells (HUVECs) in 24-well tissue-culture plates for 
12 hours. Basal (12 hour) and substance P-stimulated (30 min) NO production was mea- 
sured (chemiluminesence). The HUVECs used for measuring basel NO production were 
lysed and both endothelial nitric oxide synthase (eNOS) protein expression (ELISA) and 
eNOS activity (L-arginine to L-citrulline conversion) were determined. 
Results: EDV was not significantly different between HS and LS (0.1:L~0.1 vs 1.1+1.1%, 
p=0.50) but both were significantly reduced compared to NS (6.0~1.5%, p<0.001). There 
was no difference in nitroglycerin-mediated dilatation between the groups (p=0.34). 
HUVECs treated with HS and LS serum showed similar basal (1137+~67 vs 1418±421 
nM, p=0.70) and stimulated NO production (121+120 vs 145±87 nM, p--O.90), eNOS pro- 
tein expression (974±50 vs 888+-96 pg/ml, p=0.30) and eNOS activity (1.11±0.16 vs 
1.24_+0.19 pmol L-citrulline/min/pg eNOS, p=0.62) but all were significantly different com- 
pared to NS. Serum cotinine level and pack year cigarette exposure both were signifi- 
cantly different between HS and LS (286.+26 vs 140~55 ng/ml, p<0.001; and 13+_3.5 vs 
0.7±0.2 pk/yr, p<0.001, respectively). 
Concluelons: These results indicate that both in vivo and in vitro, light smoking may 
have similar detrimental effects on EDV and NO biosynthetic pathway as does heavy 
smoking. These data may have important implications in determining what amount of cig- 
arette exposure imparts cardiovascular isk. 
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115i-69 Endogenous Inhibitor of Nitric Oxide Synthaee: 
Differential Effects in Canine Vaeculature 
David G. Cable. Marilyn R. Oeitjen, Hartzell V. Schaff, Mayo Clinic and Mayo Foundation, 
Rochester, Minnesota. 
Background - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric 
oxide synthase, produced during protein metabolism, but little is known regarding its 
direct vasoactive properties in different arterial beds. 
Methods - Segments of canine coronary, renal, and femoral artedes were pretreated 
with increasing concentrations of ADMA (10-4-10 -6 M), and endothelial function evalu- 
ated in organ chambers. 
Results - In coronary arteries, ADMA inhibited relaxations to acetylcholine but not cal- 
cium ionophore. This inhibition was significant with the highest concentrations of ADMA, 
such that vessels exposed to 10 .4 and 10 .5 M (P<0.001), but not 10 .6 M, ADMA demon- 
strated significant inhibition to endothelium-dependent relaxations to acetylcholine (10 .9. 
10 "s M, n=7) following contraction with prostaglandin F2~(2x10 .6 M). Receptor-indepen: 
dent relaxations to calcium ionophore (10"9-10 "6 M, n=7), however, were not inhibited 
with any concentration of ADMA in canine coronary arteries. The effect of ADMA on ace- 
tylcholine-mediatad relaxations was shown to be competitive inhibition of the nitric oxide 
synthase pathway, as the addition of L-arginine (10 .3 M), but not D-arginine (10 .3 M), 
reversed the effect produced by 10 .5 M ADMA. Further, ADMA did not alter endothelium- 
independent relaxations to sodium nitroprusside (10-9-104 M, n=7). Peripheral arteries 
were more sensitive to ADMA than coronary arteries. Femoral and renal arteries (n=7) 
demonstrated significant ADMA inhibition to receptor-dependent relaxation induced by 
acetylcholine (n=7, P=0.03 and 0.01, respectively) and to receptor-independent relax- 
ations induced by calcium ionophore (n=7, P=0.02 and P=0.01, respectively). 
Concluelone - Altered endothelium-dependent relaxation to asymmetric dimethylargin- 
ine is most marked in femoral and renal, compared to coronary, arteries. This altered 
responsiveness to ADMA in coronary arteries may represent a protective effect in the 
coronary circulation to pathophysiologic states. 
1151-71 Endothelial Function Is Impaired in Treated Depression 
Andrew J. Broadlev. Ania Korzsun, Christopher J. Jones, Michael P. Frenneaux, 
University of Wa/es Col~age of Medicine, Cardiff, United Kingdom. 
Background: Depression is a major world wide health problem and an independent dsk 
factor for coronary heart disease (CHD) events. The mechanism of increased CHD risk is 
unknown. One possibility is endothelial dysfunction (ED), recently demonstrated in 
untreated epression, and a characteristic of other risk factors for CHD such as smoking, 
diabetes, and hypemhotestarolaemia. ED, characterised by impaired flow-mediatad 
release of the vasodilator nitric oxide (NO), is associated with atherogenesis and 
increased CHD events. We measured NO-dependent flow-mediated ilatation (FMD) in 
a group of patients with treated depression and age-matched controls. All subjects were 
free of all other risk factors for CHD. 
Methods: FMD of the brechial artery was assessed using high resolution ultrasound in 12 
patients with treated major depression (mean age 39, range 24 to 51, 6 male) and com- 
pared to that in 9 healthy controls (mean age 37, range 24 to 55, 7 male). GTN-induced, 
endothetium-independent dilatation was also assessed to confirm normal smooth muscle 
responses. 
Results: Values are mean +/- SEM percent brachial artery dilatation. FMD was signifi- 
cantly impaired in the treated depression group compared to the controls (-0.7% +/- 1.7% 
versus 5.9% +/- 1.0%, p = 0.004). In contrast, endothelium-independent dilatation was 
similar in both groups (18.5% +/- 2.4% versus 19.1% +/- 2.5%, p = NS). 
Conclusions: In patients with treated depression who had no other known risk factors for 
CHD, there was ED indicated by absence of FMD. ED with reduced NO activity may be 
the mechanism by which depression increases the risk of CHD. Our data suggest that, 
unlike in hypertension, smoking and hyperoholestarolaemia, ED and increased CHD risk 
may not be reversed by current conventional pharmacological treatment of depression. 
1151-72 Functional Act ivat ion of Inducible Nitric Oxide Synthase 
Closely Related to the Severity of Heart Failure 
Yutaka Ishibashi, Nobuyuki Takahashi, Shuzo Ohata, Shin-ichi Inoue, Yoko Ohta, Harumi 
Katoh, Nobuyuki Oyake, Yo Murekami, Toshio Shimada, Shimane Medical Universi~ 
/zumo, Japan. 
Background: We previously demonstrated that inducible nitric oxide synthase (iNOS) is 
activated in the forearm tissue of patients with congestive heart failure (CHF). In the 
present study we investigated whether the functional activation of iNOS is related with 
the severity of heart failure. 
Methods: We examined the effects of a selective iNOS inhibitor, aminoguanidine (100 
!Jmol/5min), and non-selective NOS inhibitor, L-NMMA (100 i~mol/5min), on forearm 
blood flow (FBF) using venous occlusive plethysmography in 15 patients with CHF and 
10 normal control subjects. In all of these subjects, basel plasma BNP and serum inter- 
leukin 6 (IL-6) levels were measured. Arterial and venous plasma concentrations of 
nitrite/nitrete (NOx) were measured at baseline and after injection of each drug. The 
selectivity of aminoguanidine as a selective iNOS inhibitor was evaluated from FBF 
response during co infusion of acetylcholine and either drug in additional 5 normal sub- 
jects. 
Results: Aminoguanidine significantly attenuated FBF by 15±7% in the patients group, 
however did not alter FBF in the control group. In contrast, L-NMMA significantly reduced 
